FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience.
Affiliation
Department of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, TorontoIssue Date
2016-09-06
Metadata
Show full item recordAbstract
FOLFIRINOX has been shown to significantly increase both overall survival (OS) and progression-free survival (PFS) in metastatic pancreas cancer. There is limited data regarding the treatment of locally advanced pancreatic cancer. We present a retrospective study of patients with both locally advanced and metastatic pancreas cancer using FOLFIRINOX as first-line therapy in our centre.Citation
FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience. 2016, 115 (6):649-54 Br J CancerJournal
British Journal of CancerDOI
10.1038/bjc.2016.222PubMed ID
27467054Type
ArticleLanguage
enISSN
1532-1827ae974a485f413a2113503eed53cd6c53
10.1038/bjc.2016.222
Scopus Count
Collections
Related articles
- Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy.
- Authors: Portal A, Pernot S, Siauve N, Landi B, Lepère C, Colussi O, Rougier P, Zaanan A, Verrière B, Taieb J
- Issue date: 2014 Apr
- FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.
- Authors: Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, El-Rayes BF, Wang-Gillam A, Lacy J, Hosein PJ, Moorcraft SY, Conroy T, Hohla F, Allen P, Taieb J, Hong TS, Shridhar R, Chau I, van Eijck CH, Koerkamp BG
- Issue date: 2016 Jun
- 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy.
- Authors: Lee MG, Lee SH, Lee SJ, Lee YS, Hwang JH, Ryu JK, Kim YT, Kim DU, Woo SM
- Issue date: 2013
- Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma.
- Authors: Mahaseth H, Brutcher E, Kauh J, Hawk N, Kim S, Chen Z, Kooby DA, Maithel SK, Landry J, El-Rayes BF
- Issue date: 2013 Nov
- Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.
- Authors: Stein SM, James ES, Deng Y, Cong X, Kortmansky JS, Li J, Staugaard C, Indukala D, Boustani AM, Patel V, Cha CH, Salem RR, Chang B, Hochster HS, Lacy J
- Issue date: 2016 Mar 29